The purpose of this phase 2 study was to determine the activity and safety of 6 cycles of bendamustine and 8 rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary endpoint was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% IC 35.6-60.2), and 86% (IC 75.0-92.8). The most common grade 3/4 adverse events were neutropenia (43%), thrombocytopenia (7%), anemia (4%); whereas the rate of febrile neutropenia was very low (3%). At a median follow up of 22 months (1-43 months), 2-year progression free survival was 89% (IC: 79-95), and 2-year overall survival was 96% (IC: 87-99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL.

A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma / Luminari, Stefano; Goldaniga, Maria; Cesaretti, Marina; Orsucci, Lorella; Tucci, Alessandra; Pulsoni, Alessandro; Salvi, Flavia; Arcaini, Luca; Carella, Angelo Michele; Tedeschi, Alessandra; Pinto, Antonello; Stelitano, Caterina; Baldini, Luca. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 57:4(2016), pp. 880-887. [10.3109/10428194.2015.1091934]

A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma

LUMINARI, Stefano;CESARETTI, Marina;
2016

Abstract

The purpose of this phase 2 study was to determine the activity and safety of 6 cycles of bendamustine and 8 rituximab (RB) as first-line treatment of adult patients with advanced stage non-follicular indolent non-Hodgkin lymphomas (INFL). The primary endpoint was the complete response rate (CRR) with expected CRR of 75%. Sixty-nine patients were enrolled; median age was 65 years (45-75), 65% were male, 93% of patients had stage IV disease. Complete and overall response rates were 48% (95% IC 35.6-60.2), and 86% (IC 75.0-92.8). The most common grade 3/4 adverse events were neutropenia (43%), thrombocytopenia (7%), anemia (4%); whereas the rate of febrile neutropenia was very low (3%). At a median follow up of 22 months (1-43 months), 2-year progression free survival was 89% (IC: 79-95), and 2-year overall survival was 96% (IC: 87-99). RB combination is active and well tolerated in patients with advanced stage previously untreated INFL.
2016
8-feb-2016
57
4
880
887
A Phase II study of Bendamustine in Combination With Rituximab as Initial Treatment for Patients With Indolent non-follicular non-Hodgkin's Lymphoma / Luminari, Stefano; Goldaniga, Maria; Cesaretti, Marina; Orsucci, Lorella; Tucci, Alessandra; Pulsoni, Alessandro; Salvi, Flavia; Arcaini, Luca; Carella, Angelo Michele; Tedeschi, Alessandra; Pinto, Antonello; Stelitano, Caterina; Baldini, Luca. - In: LEUKEMIA & LYMPHOMA. - ISSN 1042-8194. - 57:4(2016), pp. 880-887. [10.3109/10428194.2015.1091934]
Luminari, Stefano; Goldaniga, Maria; Cesaretti, Marina; Orsucci, Lorella; Tucci, Alessandra; Pulsoni, Alessandro; Salvi, Flavia; Arcaini, Luca; Carell...espandi
File in questo prodotto:
File Dimensione Formato  
A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non follicular non Hodgkin lymphoma.pdf

Accesso riservato

Tipologia: Versione pubblicata dall'editore
Dimensione 1 MB
Formato Adobe PDF
1 MB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1082047
Citazioni
  • ???jsp.display-item.citation.pmc??? 3
  • Scopus 11
  • ???jsp.display-item.citation.isi??? 11
social impact